ModifiedCapital BluecrossPolicy MP 6.064

Medical Management of Obstructive Sleep Apnea Syndrome

Defines medical necessity, coverage criteria, and device management for CPAP, BiPAP, APAP, oral appliances, and other therapies for adults and pediatric patients with obstructive sleep apnea (OSA). Applies to Capital Bluecross members and their treating providers.

Policy Summary

PayerCapital Bluecross

PolicyMedical Management of Obstructive Sleep Apnea Syndrome

Policy CodePolicy MP 6.064

Change TypeMajor review with coding reclassification and investigational additions

Effective DateAug 1, 2025

Next Review Date

Key ActionDocument objective adherence (≥2 hours on 70% of nights over a continuous 30-day period) and complete a face-to-face re-evaluation at the end of the initial 90 days to support continuation of PAP therapy.

SourceLink

POLICY UPDATE CHANGES

Created new policy for Medical Management of Obstructive Sleep Apnea and added investigative (INV) statement for Neuromuscular Electrical Tongue Stimulation.

Moved code A7049 for EPAP from medically necessary to investigational.

Added CPT codes 0964T-0966T to the policy via administrative update.

Removed Benefit Variations Section and updated Disclaimer.

5 yearsreasonable useful lifetime for PAP device replacement

>=15/hrAHI/RDI/REI threshold for clinically significant OSA

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Medical Necessity

APAP (Auto-adjusting PAP) Titration

APAP may be considered medically necessary for titration when ANY of the following are met:

APAP - moderate/severe OSA: APAP is medically necessary if AHI, RDI, or REI ≥ 15 events/hourAHI/RDI/REI >= 15

Supported by policy criteria for APAP titration

APAP - symptomatic OSA: APAP is medically necessary if AHI, RDI, or REI ≥ 5 events/hour with documentation of one or more signs or symptoms associated with OSA (e.g., excessive daytime sleepiness, hypertension, cardiovascular disease, or stroke)AHI/RDI/REI >= 5 + symptoms

Supported by policy criteria for APAP titration

APAP - change in clinical status: APAP may be used when there is a significant change in weight or change in symptoms suggesting that CPAP should be adjusted or possibly discontinuedSignificant clinical change

Supported by policy criteria for APAP titration

Initial CPAP Therapy

CPAP may be considered medically necessary when ONE of the following is met:

Adult CPAP - AHI/RDI/REI ≥15: For adults: AHI, RDI, or REI ≥ 15 events/hour>=15

Adult diagnostic threshold per policy

Adult CPAP - AHI/RDI/REI ≥5 with symptoms: For adults: AHI, RDI, or REI ≥ 5 events/hour with one or more signs or symptoms associated with OSA (e.g., excessive daytime sleepiness, hypertension, cardiovascular disease, or stroke)>=5 + symptoms

Adult symptomatic threshold per policy

Pediatric CPAP - AHI/RDI ≥5: For pediatric patients: AHI or RDI ≥ 5 events/hour>=5 pediatric

Bilevel Positive Airway Pressure (BiPAP)

Bilevel PAP may be considered medically necessary when:

BiPAP after CPAP failure: Bilevel PAP is medically necessary in individuals with clinically significant OSA who have failed a prior trial of CPAPPrior CPAP failure

Policy indicates BiPAP when CPAP trial fails

BiPAP when more effective in lab: Bilevel PAP is medically necessary when bilevel PAP is found to be more effective than CPAP during sleep laboratory testingLab demonstrates greater effectiveness

Policy allows BiPAP when lab efficacy demonstrated

Continuation of Therapy

Continued CPAP, BiPAP, or APAP therapy is medically necessary when BOTH of the following are met:

Objective adherence: Objective evidence of adherence defined as use of positive airway pressure ≥2 hours for 70% of nights in a continuous 30-day period assessed at the end of the initial 90 days of use>=2 hours on 70% of nights over 30 days

Adherence definition and timing per policy

Face-to-face re-evaluation: Face-to-face clinical re-evaluation (in-person or via telehealth) by the treating provider with documentation that symptoms of OSA are improvedFace-to-face re-eval at end of initial 90 days

Clinical re-evaluation requirement per policy

PAP Device Replacement

Replacement of PAP devices is medically necessary under the following conditions:

End of reasonable useful lifetime: Replacement is medically necessary at the end of the five-year reasonable useful lifetime (RUL)5 years

RUL replacement requirement per policy

Loss, theft, or irreparable damage during RUL: If replaced during the 5-year RUL because of loss, theft, or irreparable damage due to a specific incident, replacement is medically necessary without requirement for a new clinical evaluation, sleep test, or trial periodSpecific incident during RUL

Policy allows replacement after incident without new evaluation

Device failure prior to RUL: Replacement prior to the end of the RUL is medically necessary if the device is non-functional due to wear and tear not related to misuse or abuse

Intraoral Appliances (Mandibular Advancement/Tongue-Retaining)

Intraoral appliances (mandibular advancement/positioning or tongue-retaining devices) may be medically necessary when ALL of the following are met:

OSA severity: OSA defined by AHI ≥ 15 events/hour OR AHI ≥ 5 events/hour with one or more signs or symptoms associated with OSA (e.g., excessive daytime sleepiness, hypertension, cardiovascular disease, or stroke)AHI >=15 or >=5 + symptoms

Severity criteria per policy

Prior CPAP trial failed/contraindicated/refused: A trial with CPAP, BiPAP, or APAP has failed, is contraindicated, or was refusedPrior CPAP/BiPAP/APAP trial failed/contraindicated/refused

Prior PAP trial required before oral appliance per policy and step-therapy

Prescriber and custom fitting: Device is prescribed by a treating physician and custom fitted by qualified dental personnel

Investigational Therapies

The following are considered investigational due to insufficient evidence:

PAP-NAP (abbreviated daytime sleep study): Abbreviated daytime sleep study (PAP-NAP) as a supplement to standard sleep studies is considered investigationalInvestigational

Policy lists PAP-NAP as investigational

Palate and mandible expansion devices are considered investigationalInvestigational

Policy lists palate/mandible expansion as investigational

EPAP and oral pressure therapy: Nasal expiratory positive airway pressure (EPAP) and oral pressure therapy devices are considered investigationalInvestigational

Policy lists EPAP and oral pressure therapy as investigational

Diagnosis criteria and severity classification

Covered diagnosis and diagnostic approach when standard testing is performed

Diagnostic standard

Severity thresholds: Use AHI/RDI/REI thresholds to classify mild/moderate/severe OSA per definitionsMild 5-<15; Moderate 15-<30; Severe ≥30 (adults); pediatric thresholds differ
Severity classification per policy

Scoring definitions: Apnea and hypopnea scoring definitions and the distinctions between AHI, RDI, and REI are as defined in Table 1 (policy) and should be used for diagnostic reportingPer Table 1 scoring criteria

Reference to Table 1 definitions in policy

Treatment options

Treatment options and sequencing

Pediatric sequencing: In children, adenotonsillectomy is usually first-line; CPAP is an option for children who are not surgical candidates or who have inadequate response to surgeryPediatric first-line: adenotonsillectomy

Policy specifies first-line pediatric surgical approach

Adult medical management: Adult treatment options include weight loss, avoidance of stimulants, positional therapy, oral appliances, and PAP therapies (CPAP, BiPAP, APAP); sequencing considers trials of PAP before oral appliances except when PAP is contraindicated or refusedPer individual clinical context

Policy references sequencing and step-therapy considerations

Therapies: PAP, oral appliances, neuromuscular stimulation, and novel treatments

Covered when medically necessary according to clinical context and member benefits; policy summarizes evidence-based stances:

PAP therapies (CPAP/APAP/BiPAP): Conventional medical management includes CPAP, APAP, and bilevel PAP; evidence from RCTs, systematic reviews, and cohort studies supports improvements in symptoms, function, and quality of life; APAP may be used for titration or treatmentSee clinically significant OSA definitions

Evidence sufficient to determine improved net health outcome for PAP therapies

Oral appliances are an accepted therapy for mild-to-moderate OSA and may be used when patients refuse or cannot tolerate PAP; systematic reviews show efficacy but generally less effective than CPAPMild-to-moderate OSA per policy definitions

Evidence supports use as alternative to PAP

Neuromuscular tongue stimulation (eXciteOSA): Evidence includes 1 RCT and several single-arm studies with mixed outcomes; RCT showed improvements in some respiratory indices but not ESS; studies limited by small size and short follow-up — evidence insufficient to determine net health outcome

Investigational and coding actions

Policy-level coverage actions recorded in provided segments

Neuromuscular electrical tongue stimulation - investigational: Neuromuscular Electrical Tongue Stimulation is listed as investigational (INV)

Added INV statement in policy history

EPAP code reclassification: HCPCS code A7049 for EPAP was moved from medically necessary to investigational (INV)

Code status changed in policy history

Administrative code additions: CPT codes 0964T–0966T were added to the policy in an administrative update

Administrative update recorded in policy history

Prefabricated or off-the-shelf intraoral appliances (non–custom fitted devices) are designated investigational under this policy. Coverage for intraoral appliances requires that the device be prescribed by a treating physician and custom fitted by qualified dental personnel; devices that do not meet these criteria are considered investigational and not covered.

Replacement of PAP devices that occurs because of misuse, abuse, or negligence by the individual is considered investigational under this policy and therefore is not a covered indication for device replacement.

Use of overnight oximetry alone is inadequate for the diagnosis of obstructive sleep apnea and cannot substitute for an attended polysomnography (PSG) or a validated home sleep apnea test. A follow-up PSG or home sleep apnea test is required to confirm or exclude OSA when oximetry is used as an initial assessment.

Devices and procedure codes that are listed in the policy as investigational (for example, HCPCS code A7049 and associated procedure codes) are classified as investigational and therefore are not covered per this policy.

The former Benefit Variations section was removed as an administrative update. Providers should consult the payer or product-specific benefit manuals for any local benefit variations that may affect coverage.

The use of an abbreviated daytime sleep study (PAP‑NAP) as a supplement to standard diagnostic sleep studies is considered investigational. Current evidence is insufficient to support its routine use as an adjunct to standard PSG or validated home sleep apnea testing.

The policy describes a range of novel diagnostic and treatment devices (for example, palate/mandible expansion devices, EPAP, oral pressure therapy, and positional vibration devices) and notes that many devices are FDA‑cleared. However, listing an FDA clearance in the policy does not by itself establish coverage; coverage determinations depend on the clinical indication, evidence of efficacy, and applicable member benefit rules.

For neuromuscular electrical tongue stimulation (eXciteOSA) and several other novel OSA treatments, the evidence base is limited (including small randomized trials and single‑arm studies) and is insufficient to determine whether these therapies improve net health outcomes. These technologies are therefore considered investigational or not medically necessary pending stronger evidence.

HCPCS code A7049 (nasal expiratory positive airway pressure, EPAP) has been reclassified from medically necessary to investigational in this policy update. Devices or services designated investigational in the policy are not considered medically necessary and are not covered.

Coding and Billing Positions

Document does not list specific CPT/HCPCS/ICD-10 codes in this partmixed

No codes listed

FDA product codes (devices)mixed

LQZ	FDA product code for oral appliances for snoring and mild-moderate OSA (510(k) cleared devices listed).

FDA product codes (PAP)mixed

BZD	FDA product code for certain PAP devices (510(k) cleared).
MNT	FDA product code referenced for PAP devices.

Investigational / Not CoveredHCPCSNot Covered

A7049	Investigational; therefore, not covered (listed alongside various procedure codes)
E0490	Procedure code listed under investigational
E0491	Procedure code listed under investigational
E0492	Procedure code listed under investigational
E0493	Procedure code listed under investigational
E0530	Procedure code listed under investigational
E1399	Procedure code listed under investigational

Covered when medically necessarymixedCovered

A7034	Covered when medically necessary (listed with multiple A7xxx crosswalks)
A7046	Covered when medically necessary (listed mapping to durable medical equipment codes)
E0470	Covered when medically necessary (listed)
E0471	Covered when medically necessary (listed)
E0472	Covered when medically necessary (listed)
E0485	Covered when medically necessary (listed)
E0486	Covered when medically necessary (listed)
E0561	Covered when medically necessary (listed)
E0562	Covered when medically necessary (listed)
E0601	Covered when medically necessary (listed)

1–10 of 19

1/2

Diagnosis CodesICD-10

G47.33	Obstructive sleep apnea (adult)
R06.81	Apnea, not elsewhere classified
R40.0	Somnolence
G47.30	Sleep apnea, unspecified
G47.8	Other sleep disorders
G47.9	Sleep disorder unspecified

EPAP device code (reclassified)HCPCSExperimental

A7049

Nasal expiratory positive airway pressure (EPAP) device

Newly added CPT codesCPT

0964T	Added CPT code (as recorded in administrative update)
0965T	Added CPT code (as recorded in administrative update)
0966T	Added CPT code (as recorded in administrative update)

AHI/RDI/REI thresholds (adults and pediatrics)

Adult — primary threshold>= 15 events/hour (AHI, RDI, or REI)

Adult — symptomatic threshold>= 5 events/hour (AHI, RDI, or REI) with documentation of one or more OSA signs or symptoms (e.g., excessive daytime sleepiness, hypertension, cardiovascular disease, or stroke)

Pediatric — primary threshold>= 5 events/hour (AHI or RDI)

Pediatric — symptomatic threshold>= 1.5 events/hour (AHI or RDI) with excessive daytime sleepiness, behavioral problems, or hyperactivity

Provider Actions, Prior Authorization, and Documentation

Documentation Required

Medical necessity requirements for PAP therapy

Medical necessity for PAP therapy (CPAP/APAP/BiPAP) is determined by objective diagnostic thresholds and documented clinical need. CPAP, APAP, or BiPAP is medically necessary when diagnostic testing demonstrates OSA meeting policy criteria (e.g., AHI, RDI, or REI ≥15 events/hour, or ≥5 events/hour with ≥1 OSA-related sign or symptom; pediatric thresholds vary). Continued therapy requires objective adherence (use ≥2 hours on 70% of nights over a continuous 30-day period assessed at the end of the initial 90 days) AND a face-to-face clinical re-evaluation documenting symptomatic improvement. Providers must document diagnostic test results, adherence data, and clinical re-evaluation notes to support medical necessity.

Diagnostic thresholds: AHI/RDI/REI ≥15, OR ≥5 with symptoms; pediatric criteria: AHI/RDI ≥5, or ≥1.5 with symptoms.
Continuation criteria: adherence ≥2 hours/night on 70% of nights over a continuous 30-day period AND face-to-face re-evaluation at end of initial 90 days.

Prior Authorization

Product-specific prior authorization and benefit variations

Background and Scope

Obstructive sleep apnea (OSA) is characterized by repetitive upper‑airway obstruction during sleep and is diagnosed using event indices such as the Apnea‑Hypopnea Index (AHI), Respiratory Disturbance Index (RDI), or Respiratory Event Index (REI). Clinically significant OSA in adults is defined as AHI/RDI/REI ≥15 events/hour, or AHI/RDI/REI ≥5 events/hour with one or more OSA‑related signs or symptoms (for example, excessive daytime sleepiness, hypertension, or cardiovascular disease). Polysomnography (PSG) is the criterion standard for diagnosis; home sleep apnea testing may be used when appropriate devices record the required parameters.

Definitions and Key Concepts

Clinically significant OSA — summary

Adult clinically significant OSAAHI or RDI >= 15 events/hour; OR AHI/RDI 5–14 events/hour with documented OSA symptoms (e.g., excessive daytime sleepiness, impaired cognition, mood disorders, insomnia) or hypertension/ischemic heart disease/stroke

Pediatric clinically significant OSAAHI or RDI >= 5 per hour; OR AHI/RDI >= 1.5 per hour with excessive daytime sleepiness, behavioral problems, or hyperactivity

APAP titration criterion (context)APAP may be used for titration when clinically significant OSA thresholds are met (adult >=15 or >=5 with symptoms)

Objective adherence (definition used for continued therapy)

Objective adherence definitionUse of positive airway pressure >=2 hours for 70% of nights in a continuous 30-day period

Assessment timing

Policy Revision History

2025-06-24administrative_update

Removed Benefit Variations section and updated the policy disclaimer (administrative).

2025-06-10administrative_update

Added CPT codes 0964T, 0965T, and 0966T to the policy (administrative).

2025-02-03major_reviewLatest

Policy Summary

PayerCapital Bluecross

PolicyMedical Management of Obstructive Sleep Apnea Syndrome

Policy CodePolicy MP 6.064

Change TypeMajor review with coding reclassification and investigational additions

Effective DateAug 1, 2025

Next Review Date

SourceLink

On This Page

Apnea‑Hypopnea Index (AHI) / Respiratory Disturbance Index (RDI) — definitions and thresholds

Apnea definition (adults)Drop in airflow >=90% of pre-event baseline for at least 10 seconds

Hypopnea definition (adults)Peak airflow reduction >=30% for >=10 seconds with >=4% arterial oxygen desaturation or an associated arousal

AHI definitionAverage number of apneas plus hypopneas per hour of sleep

RDI / REI distinctionRDI = apneas, hypopneas, and RERAs per hour of sleep; REI = events per hour of monitoring time (used when EEG sleep time not available)

Billing Rule

Code additions and reclassification affecting prior authorization

Recent coding updates affect prior authorization and claims processing. Codes 0964T–0966T were added to the policy code list (added 06/10/2025). EPAP-related code A7049 has been reclassified to investigational and may be denied. Providers must use the current code list when requesting prior authorization and submitting claims.

Added codes: 0964T, 0965T, 0966T (6/10/2025).
A7049 (EPAP) moved to investigational — claims for A7049 may be denied.
Confirm use of updated code set for prior authorization requests and claim submission.

Documentation Required

Inadequate diagnostic testing

Overnight oximetry alone is inadequate to establish a diagnosis of OSA. The criterion standard is attended polysomnography (PSG); many home sleep apnea tests (HSAT) are acceptable when appropriate, but portable single-channel oximetry does not substitute for PSG or an HSAT that records respiratory parameters. If an inadequate test (e.g., oximetry only) is used, a follow-up PSG or HSAT is required to confirm or exclude OSA prior to authorizing PAP therapy.

Overnight oximetry alone is inadequate — obtain PSG or an appropriate HSAT to confirm diagnosis.
PSG (attended) is the criterion standard and documents sleep staging and respiratory parameters.

Denial Risk

Investigational items may be denied

Items and technologies designated investigational in this policy are not covered and may be denied. Examples include devices or therapies that do not meet the stated clinical criteria or are explicitly listed as investigational (see coding section). Providers requesting coverage for investigational items should include evidence supporting clinical benefit; absent such evidence, prior authorization may be denied.

Investigational items: devices or therapies listed as investigational in the coding section (e.g., certain device codes listed as investigational).
Prefabricated/off-the-shelf intraoral appliances are considered investigational and not covered.

Denial Risk

EPAP investigational status triggers potential denial

EPAP devices (code A7049) have been reclassified to investigational status in this policy. Claims or prior authorization requests for EPAP (A7049) may be denied. Confirm alternative covered therapies and document rationale if requesting EPAP devices despite policy classification.

A7049 (EPAP) moved from medically necessary/miscategorized status to investigational — potential denial risk.
If considering EPAP, document clinical rationale and check for alternative covered PAP options.

Documentation Required

Replacement at 5-year RUL requires clinical evaluation

Replacement after the five-year reasonable useful lifetime (RUL) requires an in-person evaluation by the treating practitioner documenting the beneficiary continues to use and benefit from the PAP device. No new sleep test or trial period is required at RUL-based replacement.

At end of 5-year RUL: in-person evaluation documenting continued use and benefit is required.
No new diagnostic sleep study or trial period required for RUL-based replacement.

Documentation Required

Replacement during the 5-year RUL for loss, theft, or irreparable damage

If a PAP device is replaced during the 5-year RUL because of loss, theft, or irreparable damage from a specific incident, a new clinical evaluation, sleep test, or trial period is not required. Document the incident and circumstances leading to replacement.

Replacement during 5-year RUL for loss/theft/irreparable damage: no new evaluation or sleep test required.
Document incident details and justification for early replacement in the medical record.

Documentation Required

Document medical necessity and confirm eligibility

Coverage determinations depend on member benefit terms and eligibility on the date of service. Providers must document medical necessity, include diagnostic test results, treatment trials, adherence data, and clinical re-evaluations in the medical record to support prior authorization and claims. Contact Provider Services or Member Services for questions about specific member coverage.

Verify member eligibility and benefit limitations on date of service.
Include documentation: diagnostic study reports, AHI/RDI/REI values, signs/symptoms, prior therapy trials, adherence reports, and face-to-face re-evaluation notes.

Billing Rule

Documentation and coding note

Providers must reference the policy history and current coding lists when submitting claims. Administrative updates (e.g., addition of 0964T–0966T and reclassification of A7049) may affect prior authorization requirements and claim adjudication. Use the policy’s coding section as a guide but verify code coverage with the member’s benefit plan.

Refer to policy coding section and the documented policy history for recent administrative changes.
Confirm whether newly added or reclassified codes require prior authorization or are subject to investigational exclusion before submission.

Step Therapy

Oral appliance therapy requires prior trial of PAP therapy

Oral appliance therapy (custom intraoral appliances) is allowed only after a trial of CPAP/BiPAP/APAP has failed, is contraindicated, or is refused. Appliances must be prescribed by a treating physician and custom fitted by qualified dental personnel; prefabricated/off-the-shelf devices are investigational.

Requirement: documentation of failed, contraindicated, or refused trial of PAP therapy before approving oral appliance.
Oral appliances must be custom-fitted and prescribed by a physician; document absence of temporomandibular dysfunction or periodontal disease.

Note

Treatment sequencing and use of APAP for titration

Treatment sequencing should be documented: conservative measures (weight loss, positional therapy) and surgical options in children (adenotonsillectomy) are first-line where appropriate. For adults, document prior attempts at weight loss, positional measures, and PAP therapy trials before transitioning to alternative devices (e.g., oral appliances). A diagnostic study may be followed by an APAP trial to titrate pressure and determine fixed CPAP settings.

Sequence: weight loss/behavioral measures → positional therapy → PAP therapy (APAP/CPAP/BiPAP) → oral appliances if PAP fails/contraindicated/refused.
APAP trial after diagnostic study may be used to evaluate efficacy and determine fixed CPAP pressure; document outcomes of APAP titration.